ArticleBlood2022
Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma.
Article in Blood, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT03105336 (A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma), which is not on this map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 2 Multicenter Study of Axicabtagene Ciloleucel in Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma (iNHL)
Who cites it
31 citing papers in PubMed, 59 citations in OpenAlex.
- Trial
- Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.Signal transduction and targeted therapy · 2026Review
- Article
- Design and Implementation of Observational Studies Emulating a Target Trial.JAMA network open · 2026Article
- Predictive value of maximum tumor dissemination (Dmax) in lymphoma patients treated with CD19-specific CAR T-Cells.Cancer imaging : the official publication of the International Cancer Imaging Society · 2025Article
- Article
- A SWOT-Consensus for CAR-T in Follicular Lymphoma: Fine Tuning of Patient Journey and Selection.Hematological oncology · 2025Article
- CAR-T cell therapy for cancer: current challenges and future directions.Signal transduction and targeted therapy · 2025Review
- The prognostic value of POD24 in relapsed/refractory follicular lymphoma-A SCHOLAR-5 analysis.EJHaem · 2025Article
- Chimeric antigen receptor T-cell and bispecific antibody therapies for follicular lymphoma: Recent advances and future prospects.Journal of clinical and experimental hematopathology : JCEH · 2025Review
- Approved CAR-T therapies have reproducible efficacy and safety in clinical practice.Human vaccines & immunotherapeutics · 2024Review
- Propensity Score Methods for Confounding Control in Observational Studies of Therapeutics for COVID-19 Infection.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2024Article
- Impact of immunological aging on T cell-mediated therapies in older adults with multiple myeloma and lymphoma.Journal for immunotherapy of cancer · 2024Review
- Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis.Thorax · 2024Observational
- Challenges and Lessons Learned in Autologous Chimeric Antigen Receptor T-Cell Therapy Development from a Statistical Perspective.Therapeutic innovation & regulatory science · 2024Article
- Therapeutic Vaccines for Follicular Lymphoma: A Systematic Review.Pharmaceuticals (Basel, Switzerland) · 2024Review
- CAR-T Cell Therapy for Follicular Lymphomas.Mediterranean journal of hematology and infectious diseases · 2024Review
- The treatment of follicular lymphoma with CD19-directed chimeric antigen receptor T-cell therapy.Frontiers in oncology · 2024Review
- Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma.Journal of comparative effectiveness research · 2023Article
- Balancing considerations and qualifying conclusions for cost-effectiveness of therapies for relapsed/refractory follicular lymphoma.Blood advances · 2023Article
Corrections and comments
- Commented on by
Authors and funding
17 authors at 11 institutions in 5 countries.
Funding
Abstract
In the pivotal ZUMA-5 trial, axicabtagene ciloleucel (axi-cel; an autologous anti-CD19 chimeric antigen receptor T-cell therapy) demonstrated high rates of durable response in relapsed/refractory (r/r) follicular lymphoma (FL) patients. Here, outcomes from ZUMA-5 are compared with the international SCHOLAR-5 cohort, which applied key ZUMA-5 trial eligibility criteria simulating randomized controlled trial conditions. SCHOLAR-5 data were extracted from institutions in 5 countries, and from 1 historical clinical trial, for r/r FL patients who initiated a third or higher line of therapy after July 2014. Patient characteristics were balanced through propensity scoring on prespecified prognostic factors using standardized mortality ratio (SMR) weighting. Time-to-event outcomes were evaluated using weighted Kaplan-Meier analysis. Overall response rate (ORR) and complete response (CR) rate were compared using weighted odds ratios. The 143 ScHOLAR-5 patients reduced to an effective sample of 85 patients after SMR weighting vs 86 patients in ZUMA-5. Median follow-up time was 25.4 and 23.3 months for SCHOLAR-5 and ZUMA-5. Median overall survival (OS) and progression-free survival (PFS) in SCHOLAR-5 were 59.8 months and 12.7 months and not reached in ZUMA-5. Hazard ratios for OS and PFS were 0.42 (95% confidence interval [CI], 0.21-0.83) and 0.30 (95% CI, 0.18-0.49). The ORR and CR rate were 49.9% and 29.9% in SCHOLAR-5 and 94.2% and 79.1% in ZUMA-5, for odds ratios of 16.2 (95% CI, 5.6-46.9) and 8.9 (95% CI, 4.3-18.3). Compared with available therapies, axi-cel demonstrated an improvement in meaningful clinical endpoints, suggesting axi-cel addresses an important unmet need for r/r FL patients. This trial was registered at www.clinicaltrials.gov as #NCT03105336.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.